May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Is Intravitreal Bevacizumab an Efective Treatment for Coats Disease?
Author Affiliations & Notes
  • E. Romo-Garcia
    Retina, APEC, Mexico, Mexico
  • G. Alvarez-Rivera
    Retina, APEC, Mexico, Mexico
  • M. Gordon
    Retina, APEC, Mexico, Mexico
  • V. Kon-Jara
    Retina, APEC, Mexico, Mexico
  • M. Martinez-Castellanos
    Retina, APEC, Mexico, Mexico
  • D. Moreno-Paramo
    Retina, APEC, Mexico, Mexico
  • J. Guerrero-Naranjo
    Retina, APEC, Mexico, Mexico
  • H. Quiroz-Mercado
    Retina, APEC, Mexico, Mexico
  • Footnotes
    Commercial Relationships E. Romo-Garcia, None; G. Alvarez-Rivera, None; M. Gordon, None; V. Kon-Jara, None; M. Martinez-Castellanos, None; D. Moreno-Paramo, None; J. Guerrero-Naranjo, None; H. Quiroz-Mercado, None.
  • Footnotes
    Support Rioarronte Foundation
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 94. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Romo-Garcia, G. Alvarez-Rivera, M. Gordon, V. Kon-Jara, M. Martinez-Castellanos, D. Moreno-Paramo, J. Guerrero-Naranjo, H. Quiroz-Mercado; Is Intravitreal Bevacizumab an Efective Treatment for Coats Disease?. Invest. Ophthalmol. Vis. Sci. 2007;48(13):94.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: To evaluate the short-term safety of intravitreal bevacizumab and its effects on visual acuity and anatomical changes in patientes with Coats disease.

Methods:: Four eyes of 4 patients with Coats disease were included in a pilot study. Patients were treated at baseline with a 2.5 mg / 0.1 ml intravitreous bevacizumab injection; full opthalmologic evaluations were performed at baseline and at 1, 4, 8, 12 and 24 weeks. The evaluations included biomicroscopy, visual acuity mesurement, along with optical coherence tomography imaging and fluorescein angiography.

Results:: Average patient age was 17years old. There were no ocular or sytemic adverse events identified at the six month follow-up. Serial examinations documented an involutional response with a reduction of the subretinal fluid, exudates and macular thickness; visual acuity improved in all cases, but the improvement lasted for 3 months.

Conclusions:: Intravitreal injection of Bevacizumab was well tolerated, and resulted in a transient improvement in visual acuity, optical coherence tomography and angiographic outcome. Bevacizumab therapy could be considered in patients with Coats disease, but further studies exploring combined treatment with laser or cryotherapy should be undertaken.

Keywords: retina • retinal detachment • retinal detachment 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.